Accelerating drug development for neuroblastoma: Summary of the Second Neuroblastoma Drug Development Strategy forum from Innovative Therapies for Children with Cancer and International Society of Paediatric Oncology Europe Neuroblastoma
Phase II results from a phase I/II study to assess the safety and efficacy of weekly nab-paclitaxel in paediatric patients with recurrent or refractory solid tumours
ITCC Trials and the COVID19 Pandemic
A phase 1/2, open‐label, dose‐escalation study of midostaurin in children with relapsed or refractory acute leukaemia
Phase I results of a phase I/II study of weekly nab-paclitaxel in paediatric patients with recurrent/refractory solid tumours: A collaboration with innovative therapies for children with cancer
10 year report on the European Paediatric Regulation and its impact on new drugs for children's cancers
Outcome of children and adolescents with central nervous system tumors in phase I trials
Early phase clinical trials of anticancer agents in children and adolescents — an ITCC perspective
